Hyundai Bioscience to Conduct Global Clinical Trials for Dengue Antiviral Candidate
Hyundai Bioscience, a biotechnology company from South Korea, is focusing on global clinical development for a Dengue antiviral candidate to secure emergency use authorization. The CEO plans to conduct clinical tests targeting all Dengue virus serotypes, aiming for early administration of an effective antiviral drug. With a rise in Dengue cases globally, especially in the Americas, the need for a specific treatment is crucial. Hyundai Bioscience’s initiative in conducting extensive clinical trials signifies a significant step towards addressing the urgent need for a Dengue antiviral solution.
110 Mosquito Traps Installed at Sibu Central Market to Curb Dengue Spread
Sibu Central Market is installing 110 units of mosquito traps in collaboration with the Ministry of Health to combat the spread of dengue. The traps, designed to attract and kill aedes mosquitoes, have shown success in Peninsular Malaysia and may be expanded to other markets in the district if proven effective. With an 88% increase in dengue cases compared to last year, the initiative aims to serve as a model for controlling the disease in Sarawak.